The severe combined immunodeficient (SCID) mouse model may be used to evaluate new approaches for the treatment of acute myeloid leukemia (AML). We have previously demonstrated the killing of SCID mouse leukemia initiating cells by in vitro incubation with human GM-CSF fused to Diphtheria toxin (DT-huGM-CSF). In this report, we show that in vivo treatment with DT-huGM-CSF eliminates AML growth in SCID mice. Seven cases of AML were studied. SCID mice were treated intraperitoneally with the maximally tolerated dose of 75 g/kg/day for 7 days. Antileukemic efficacy was determined at days 40 and 80 after transplantation, by enumerating the percentages of human cells in SCID bone marrow using flow cytometry and short tandem repeat polymerase chain reaction (STR-PCR) analysis. Four out of seven AML cases were sensitive to in vivo treatment with DT-huGM-CSF at both evaluation time points. In three of these cases, elimination of human cells was demonstrated by flow cytometry and STR-PCR. One AML case showed moderate sensitivity for DT-huGM-CSF, and growth of the two remaining AML cases was not influenced by DT-huGM-CSF. Sensitivity was correlated with GM-CSFR expression. Our data show that DT-huGM-CSF can be used in vivo to reduce growth of AML and warrant further development of DT-huGM-CSF for the treatment of human AML.
Introduction
The severe combined immunodeficient (SCID) mouse may be used as a model to study normal and abnormal hemopoiesis, [1] [2] [3] [4] [5] [6] providing a unique opportunity to evaluate therapeutic interventions of hemopoietic malignancies. 5, [7] [8] [9] Among the new agents developed to treat neoplastic diseases, immunotoxins were shown to be very effective. [10] [11] [12] Preclinical studies with immunotoxins using tumor models in immunodeficient mice have yielded encouraging results. [13] [14] [15] [16] [17] Leukemic cells of more than 80% of patients with acute myeloid leukemia (AML) express functional granulocytemacrophage colony-stimulating factor receptors (GM-CSFR). [18] [19] [20] This provides a rationale to explore the utility of huGM-CSF fused to a truncated form of Diphtheria toxin (DThuGM-CSF) for AML treatment. Binding of GM-CSF to the GM-CSF-receptor leads to high affinity complex formation and is followed by internalization, thus facilitating the entrance of the catalytic domain of the Diphtheria toxin (DT) inside the target cell where it is activated in the acidic environment of the endosome. DT thereafter translocates to the cytoplasma where it ribosylates elongation factor 2, which blocks protein synthesis leading to cell death. We showed earlier that in vitro Correspondence: ACM Martens, University Hospital Utrecht, Dept Haematology, room G03-647, PO Box 85500, 3508 GA Utrecht, The Netherlands; Fax: 31 30 251 1893 The first two authors contributed equally to this manuscript Received 19 May 1998; accepted 30 July 1998 exposure of primary AML cells to DT-huGM-CSF eliminates leukemic cells with long-term leukemia initiating potential in long-term bone marrow cultures and in immunodeficient mice, whereas normal hemopoietic stem cells were spared. 21, 22 This apparent discrepancy might be explained by low levels of GM-CSFR expression on primitive normal cells 23, 24 as compared to higher levels on AML cells. Alternatively, the high level of expression of the Bcl-2 protein in primitive hematopoietic cells 25 might provide resistance towards the apoptotic cell death that is normally induced after exposure to DT-GM-CSF. 26 From our studies, we concluded that GM-CSFR on long-term leukemia initiating cells are functional in that they specifically bind the DT-huGM-CSF, which is then followed by internalization. However, the potential of DT-huGM-CSF as an in vivo antileukemic agent is as yet unknown.
In the current study we show that DT-huGM-CSF is effective for the elimination of primary AML after transplantation into SCID mice, using cell numbers which usually induce overt AML in SCID mice. The antileukemic effect was evaluated by measuring the degree of human chimerism in SCID mouse bone marrow using flow cytometric analysis and PCR of short tandem repeat sequences (STR). The latter are polymorphic tandem repetitive elements which are described in humans, 27 and may be used to assess chimerism following bone marrow transplantation. 28 STR-PCR has shown to be a highly sensitive method to assess chimerism following allogeneic bone marrow transplantation.
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Materials and methods
Human AML cells
Blood or bone marrow cells were obtained following informed consent, from seven untreated acute myelocytic leukemia (AML) patients. The AMLs were classified cytologically according to the criteria of the French-American-British Committee (FAB). 30, 31 Mononuclear cells were isolated as a buffy coat, without T cell depletion. Cells were frozen using a controlled freezing apparatus and stored in liquid nitrogen. After thawing by stepwise dilution, cell viability was assessed by eosin staining and ranged from 80 to 95%.
by blunting and ligation of the 4.2 kb NdeI-HindIII fragment of pVCDT1-IL-2. The pRKDT388 encodes amino acids 1-388 of DT and the amino acids SLNSAANKARKEAELAAATLEQ at the C-terminus of DT. Plasmids were expressed in E. coli, and the pure monomeric proteins were purified using a procedure optimized to guarantee endotoxin-free preparations as described previously. 33, 34 ADP ribosylation assay DT-huGM-CSF, DT-mGM-CSF as well as DT388 were nicked with 0.04 g trypsin for 15 min at 37°C in order to obtain certain amounts of DT fragments with catalytic activity. The reaction was stopped with soybean trypsin inhibitor (Sigma, St Louis, MO, USA). Duplicate samples of nicked fusion proteins and DT were examined for their ADP ribosyl transferase activity as previously described. 35 Briefly, ADP-ribosylation was performed in 80 l reaction mixtures containing 50 l of 0.01 mol/l Tris-HCl buffer with 1.0 mmol/l dithiothreitol, pH 8.0, 10 l of rabbit reticulocyte lysate (Promega, Madison, WI, USA), and 10 l of toxin sample. The reaction was initiated by the addition of 10 l of 0.5 mol/l 32 P-nicotinamide adenine dinucleotide (Amersham, Amersham, UK). Reaction mixtures were incubated at room temperature for 1 h and the reaction was stopped by the addition of 1 ml 10% trichloroacetic acid (TCA). The precipitate was collected by centrifugation and washed with 1 ml 10% TCA. The radioactivity was counted by standard scintillation techniques. 
H-TdR) incorporation assay
Cells (2 × 10 4 ) were cultured for 72 h in 96-well round-bottom microtiter plates in 100 l serum-free medium (SFM) containing DT-huGM-CSF, DT 388 or DT-mGM-CSF. The effects of the toxins on cell proliferation were tested in the absence of growth factors, as well as in the presence of the combination of human stem cell factor (SCF 0.1 g/ml; a gift from Amgen Biologicals, Thousand Oaks, CA, USA), human interleukin-3 (IL-3 0.025 g/ml; a gift from Gist Brocades, Delft, The Netherlands) and human granulocyte colony-stimulating factor (G-CSF 0.1 g/ml; Amgen). Eighteen hours before harvesting, 0.1 Ci 3 H-TdR (2 Ci/mmol, Amersham) was added to each well. Cells were collected using an automatic cell harvester (Skatron, Lier, Norway), and the cell-associated radioactivity was measured in a liquid scintillation counter (Pharmacia-LKB, Bromma, Sweden). In competition experiments, an excess of huGM-CSF (2 g/ml; a gift from Sandoz BV, Basel, Switzerland) was added simultaneously with DThuGM-CSF. All cultures were performed in triplicate. Data are expressed as percentage of control.
SCID mice and transplantation of AML
Female-specific pathogen-free CB17 scid/scid mice (5-8 weeks of age) were obtained from Harlan CPB (Austerlitz, The Netherlands) and housed under pathogen-free conditions in a laminar air flow unit. The mice were supplied with sterile food and acidified drinking water with 100 mg/l ciprofloxacin (Bayer, Leverkusen, Germany). The mouse plasma Ig level was determined with an ELISA using a sheep anti-mouse antibody reacting with mouse IgG and IgM (Boehringer Mannheim Biochemica, Penzberg, Germany). Mice with plasma Ig levels Ͼ40 g/ml were excluded. SCID mice were pretreated with 0.2 ml dichloromethylene diphosphonate (CL 2 MDP) liposomes, 36, 37 injected into the lateral tail vein (i.v.), on the day before transplantation of the human cells to eliminate the macrophages in spleen and liver. In addition, total body irradiation at a dose of 3.5 Gy was delivered by a 137 Cs source (Gammacell; Atomic Energy of Canada, Ottawa, Canada) adapted for the irradiation of mice. The graft size was 30 × 10 6 AML cells for all leukemia samples. The grafts, suspended in 300 l Hanks balanced salt solution (HBSS) (Gibco, Breda, The Netherlands), 16 U/ml heparin and 0.1% bovine serum albumen (BSA, Sigma), were injected i.v. AML A, C, D and G were characterized having the ability to proliferate in SCID mice without the support of human hemopoietic growth factors, whereas AML samples B, E and F were IL-3-dependent in the SCID mice. The SCID mice with AML B, E and F received 60 g of human IL-3 (Gist Brocades) in 200 l HBSS and 1% BSA (Sigma) intraperitoneally (i.p.), 3 days a week as described. 6 
Treatment of SCID mice with DT-huGM-CSF
DT-huGM-CSF, DT-mGM-CSF and DT 388 were injected i.p. in a volume of 0.1 ml PBS. Each group consisted of three to six mice. SCID mice were treated daily with DT-huGM-CSF, DT 388 , huGM-CSF or DT-mGM-CSF starting at day 3 or day 40 after transplantation. The treatment duration was 7 days. The standard DT-huGM-CSF dose was 75 g/kg i.p. except for the dose titration experiment in which the dose range was from 6.25 g/kg to 75 g/kg i.p. As a control for the specificity of DT-huGM-CSF, an excess of huGM-CSF (75 g/kg) was administered simultaneously with DT-huGM-CSF at 15 g/kg.
In the patient selected for this experiment 15 g/kg was highly effective. DT 388 was administered at 40 g/kg and DT-mGM-CSF at MTD dose in the SCID mice of 10 g/kg/day.
Tissue collections
The experiments were carried out following consent of the Institutional Ethics Committee for animal experiments. SCID mice were sacrificed using CO 2 inhalation followed by cervical dislocation in accordance with institutional animal research regulations. Cell suspensions were prepared from the bone marrow and analyzed by flow cytometry.
Flow cytometric analysis of SCID mouse derived AML cells
To quantify AML growth and to compare the immunophenotype with the initial graft samples, cells recovered from the bone marrow of SCID mice were incubated with the following mouse monoclonal antibodies to human CD markers that were used in double labeling studies in various combinations: CD34-FITC, CD34-PE, CD38-PE, HLA-DR-PE, c-kit-PE, CD33-PE, CD45-FITC. Murine IgG1-FITC and murine IgG1-PE conjugated antibodies served as isotype controls. All antibodies were obtained from Becton Dickinson (San Jose, CA, USA) with the exception of c-kit-PE (Immunotech, Marseille, France). Cells recovered from SCID mouse bone marrow staining with two antibodies specific for human hemopoietic cells were counted as human cells. 38 Bone marrow cells from non-transplanted SCID mice served as non-leukemic control marrow. Samples were analyzed using a FACScan flow cytometer and Cell Quest software (Becton Dickinson, Mountain View, CA, USA). Erythrocytes and dead cells were excluded by gating on forward and orthogonal light scatter.
PCR analysis of SCID mouse bone marrow
For the STR-PCR analysis DNA was extracted from human peripheral blood samples and from the SCID mouse bone marrow samples using the modified proteinase K, sodium dodecyl sulphate (SDS) protocol. 39 For each patient we identified both human and mouse STR-PCR primers, 29, 39 which could be used to distinguish between human and mouse cells on the basis of their electrophoretic mobility through polyacrylamide gels ( Table 1 ). The sensitivity of human specific PCR was assessed using a cell dilution assay of SCID mouse BM cells into AML cells. Likewise, the sensitivity of mouse-specific STR-PCR was assessed using a cell dilution assay of AML cells into SCID mouse bone marrow. PCR allows detection of the minor cell population, either human or mouse, at dilutions between 1/1000 and 1/10 000. This level of detection of a minor population is below the lower level of detection by FACS analysis for human in SCID BM chimerism.
STR-PCR was performed as previously described. 26, 27 Briefly, approximately 20 ng of purified DNA was amplified in a 25 l reaction with the addition of 2-5 Ci 32 P-dCTP (Amersham) to aid in subsequent detection of minor cell populations by autoradiography. Conditions for amplification cycling were: 94°C for 1 min, 55°C for 1 min, 72°C for 1 min with an additional 5 min at 72°C on the final cycle to ensure complete extension of all amplification products. Hot start PCR was performed to avoid non-specific amplification. Samples were amplified for 30 cycles on a Trioblock thermal cycler (Biometra, Maidstone, UK). One tenth of amplified product was mixed with an equal volume of formamide-dye mix and electrophoresed through 6% denaturing polyacrylamide sequencing gels. Gels were dried, mounted on autoradiographic films that were exposed for 4-24 h at −70°C. PCR was performed on material isolated from various cell dilutions using both human and mouse STR primers.
Results
Characterization of the fusion proteins
DT-huGM-CSF, DT 388 and DT-mGM-CSF were purified by the method described by Kreitman and Pastan 33 to avoid contamination of endotoxins in the final preparation. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis showed a high degree of purity of the proteins. The fusion proteins DT-mGM- CSF (57 kDa), DT-huGM-CSF (56 kDa), and DT 388 (40 kDa) migrated in the gel corresponding to their expected size ( Figure 1b ). All fusion toxins used in this study were greater than 95% pure. The ADP-ribosylation assay showed a comparable dose-dependent increase in 32 P-incorporation for all proteins ( Figure 1a ).
Antiproliferative effects of DT-huGM-CSF in a proliferation assay
The effects of the toxins on in vitro proliferation of AML cells were evaluated in the 3 H-TdR incorporation assay. Cells were stimulated with the combination of G-CSF, IL-3 and SCF. DThuGM-CSF was added in concentrations ranging from 0.001 to 1000 ng/ml for 72 h. A representative AML sample is shown in Figure 2 .
The anti-proliferative effect of DT-huGM-CSF could be prevented by an excess of huGM-CSF, showing the specificity of the growth factor toxin (GF-toxin). AML cells were resistant to DT 388 and DT-mGM-CSF (Figure 2 ). Addition of huGM-CSF to the combination SCF, IL-3 and G-CSF did not result in an additive proliferative effect. Table 2 shows the ID 50 values found for the various AMLs. The ID 50 is the DT-huGM-CSF dose required to induce a 50% inhibition of 3 H-TdR incorporation. In five of the seven AMLs, DT-huGM-CSF proved to be cytotoxic. The five sensitive samples had a mean ID 50 of 2.8 ng/ml, ranging from 0.7 to 5.0 ng/ml. AML cells from patient F and G were insensitive to DT-huGM-CSF; even a concentration of 1000 ng/ml failed to induce an antiproliferative effect.
In vivo effect of DT-huGM-CSF administration on SCID-mice
The maximal tolerated dose (MTD) in SCID mice was determined after conditioning of the animals with 3.5 Gy ␥-radiation and macrophage depletion by Cl 2 MDP liposomes. The mice were subsequently treated with graded doses of DThuGM-CSF. DT-huGM-CSF was administered by i.p. injection for a period of 7 days starting 3 days after conditioning. Table 3 lists the mortality found at the different dose levels. SCID mice receiving a daily dose of 400 g/kg/day i.p. died on the fourth day of treatment. Three out of four mice treated with 200 g/kg/day and one out of eight treated with 100 g/kg/day died on day 7 of the treatment period. The remaining mice recovered completely. In subsequent experiments the mice were treated at the MTD of 75 g/kg/day. Mortality at this dose was one out of 66 mice.
Effect of in vivo DT-huGM-CSF administration on outgrowth of AML
The effect of DT-huGM-CSF treatment on the outgrowth of leukemia in vivo was investigated for seven cases of AML. Five were sensitive to DT-huGM-CSF in the 3 H-TdR incorporation assay and two were not sensitive ( Table 2 ). Three days after transplantation daily treatment with DT-huGM-CSF (75 g/kg/day) was started for a period of 7 days. On day 40 after transplantation the SCID mice were killed and the percentage of human cells in the bone marrow was determined using a panel of monoclonal antibodies and flow cytometry (Table 4) . Whereas in groups of control mice injected with cases A, B, D and E, an average of 1.6, 10.9, 3.8 and 3.0% human cells was detected, no human cells could be detected at this time point in mice treated with DT-huGM-CSF. At day 80 of evaluation, cases A, D and E were still negative. Case B showed a reduced percentage of human cells in comparison to control mice at day 80. DT-huGM-CSF treatment of mice grafted with AML cells of patients C, F and G did not significantly reduce leukemic cell load in comparison to control mice at day 40, and for that reason, no additional analysis was performed at day 80. We also investigated whether an in vivo killing effect was achieved by administering huGM-CSF, DT388 or DT-murine GM-CSF. Figure 3a shows a control Cells from seven AML patients diagnosed according to the FAB criteria were incubated in serum-free medium without growth factors added or with GM-CSF alone or with a mixture of SCF, IL-3 and G-CSF. The ID 50 is the concentration of DT-huGM-CSF required for 50% reduction in 3 H-TdR incorporation for the cells stimulated with SCF, IL-3 and G-CSF.
Table 3
Determination of the maximally tolerated dose of DThuGM-CSF in SCID mice administered daily by i.p. injections for 7 days
No. mice Mortality (%) Table 4 Outgrowth of DT-huGM-CSF exposed vs control AML cells in SCID mice 
Phenotypic analysis of AML cells from the SCID mouse bone marrow
Cells recovered from the SCID mouse bone marrow were investigated using flow cytometry with the antibodies to CD34, CD38, CD33, CD45, HLA-DR and c-kit. The phenotypes of the AML cells recovered from the SCID mice were in general similar to the original grafts (Table 5 ). In case C the phenotype converted from 20% CD34-positive AML cells to a phenotype negative for CD34 expression. However, for this AML case this is typical when grown in SCID mice and has been reported earlier. 40 Cells from AML patient C still expressed the GM-CSFR at the time of analysis. There was no evidence of the development of a resistant population. This AML is growing very rapidly in SCID mice which might be the reason for the small difference between treated and control mice. In case D the phenotype converted from 20% c-kit positive AML cells to a phenotype Ͼ90% positive for c-kit expression. Additional support for the leukemic origin of the human cells in SCID mice was obtained by the morphologic evaluation of cytospin preparations (data not shown).
Effect of DT-huGM-CSF on overt AML in SCID mice
Treatment of SCID mice engrafted with AML was also performed in advanced stages of leukemia, at days 40 to 47 after transplantation (Table 6 ). We examined cells of patient A, which were sensitive to early treatment with DT-huGM-CSF (days 3-10). We determined the direct effect on AML cells by measuring AML cells the day after the treatment of 7 days, ie on day 47, at which time point the number of leukemic cells was significantly reduced. Thirty-three days later, ie 80 days after transplantation, significant leukemia was observed.
Dose titration of DT-huGM-CSF on the outgrowth of AML
Thus far we observed that at the MTD level most AML cells can be eliminated. Next we investigated the dose-effect relation for DT-huGM-CSF on the outgrowth of AML A by administering doses in a range from 6.25 to 75 g/kg/day (Table 7) . At every dose level used we achieved elimination of leukemic cells except in the lowest dose level group, in which in one out of three mice leukemic cells (0.2%) were detected by flow cytometric analysis. This indicates that 1/10 of the MTD dose level is already sufficient to achieve an antileukemic effect. We also investigated whether an in vivo AML cell killing effect was achieved by administering huGM-CSF, DT 388 and DT-mGM-CSF. Since the outgrowth of AML cells was not reduced significantly in all three groups, it can be concluded that DT-huGM-CSF toxicity to AML cells is specifically mediated via the huGM-CSFR.
DNA analysis
The SCID mice marrow samples in which we could not detect human cells with flow cytometry were further analyzed by PCR for human STRs in DNA extracts of bone marrow. All amplifications of mouse samples from day 40 post-treatment with mouse STR-PCR primers were negative for human cells.
STR-PCR of the bone marrow samples of treated SCID mice at day 80, transplanted with AML cells of cases A, D and E showed the presence of human cells in one mouse out of three transplanted with AML cells from case A (chimerism Ͻ0.01%), one out of three mice transplanted with AML cells from case D (chimerism Ͻ0.01%) and in one out of three mice transplanted with AML cells from case E (chimerism Ͻ1%), respectively.
Analyzing the bone marrow samples of the dose titration of DT-huGM-CSF on the outgrowth of AML case A, human STR primers indicated the presence of low numbers of human cells at the lower doses (Table 7) .
Discussion
In this study, we evaluated the utility of DT fused to huGM-CSF for in vivo treatment of human AML using the SCID/AML mouse model. We selected seven cases of AML for evaluation of which five cases (A, B, C, D and E) showed a proliferative response to huGM-CSF in vitro and were sensitive to DThuGM-CSF exposure in vitro. Case F, although showing a proliferative response to huGM-CSF and case G, that showed no proliferative response to huGM-CSF, were insensitive to DThuGM-CSF. The long-term repopulating AML cells of four out of the five huGM-CSF responsive AMLs surveyed in this study, were eliminated by a 7-day treatment with DT-huGM-CSF at the MTD of 75 g/kg/day. The low numbers of leukemic cells from cases A, D and E found on day 80, as confirmed by flow cytometry, illustrate an efficient reduction of AML growth by the DT-huGM-CSF treatment. When the percentage of leukemic cells of case A on day 80 were compared with cell dose titration experiments of case A, also analyzed on day 80, that were carried out earlier, 6 it could be concluded that at least a 3 log AML cell kill was achieved. However, human STR-PCR showed the presence of low numbers of human cells in all groups. At day 80 a low percentage of human cells was found in mice transplanted with cells of case B.
In the control groups AML-SCID mice treated with DT fused to murine GM-CSF, DT 388 , huGM-CSF or with DT-GM-CSF with an excess amount of hGM-CSF, did not interfere with AML outgrowth in the SCID mice (Figure 3) . These results are highly suggestive that leukemic stem cell reduction was mediated by specific binding of DT-huGM-CSF to the GM-CSFR of the primitive AML cells.
The response to huGM-CSF was predictive for sensitivity to DT-huGM-CSF in six out of seven cases. AML cells from case F were further examined to find a possible explanation for the insensitivity to DT-huGM-CSF. Using ␣ and ␤ GM-CSFR subunit-specific monoclonal antibodies and flow cytometry, we observed that the CD34 + subpopulation of case F (30% of all cells) showed expression of the ␣ GM-CSFR subunit, but that it lacked the ␤ subunit (data not shown). For most AMLs that were thus far studied, the SCID mouse leukemia initiating cells were restricted to the CD34 + fraction. 4 ,40,41 AML cells from case G lacked both the ␣ and ␤ GM-CSFR subunits. The Flow cytometric analysis of the human AML cell content in SCID mice bone marrow after treatment with DT-hGM-CSF only (a) or after treatment with DT-hGM-CSF with co-administration of an excess amount of hGM-CSF (b). Cells were labeled with CD34-PE and CD38-FITC. On the X-axis CD38 expression is shown (FL1-H) and CD34 expression on the Y-axis (FL2-H) Table 5 Immunophenotype of AML cells before transplantation and after growth in SCID mice failure of DT-huGM-CSF to eliminate cells of F and G and the moderate sensitivity of case C is considered to be the consequence of the absence or low expression of functional GM-CSFR on the rare population of SCID mouse leukemia initiating cells.
Mice were treated with the MTD of DT-huGM-CSF applied as a daily i.p. administration for 7 consecutive days. The schedule of prolonged delivery of growth factor toxins showed fewer side-effects while it retained a maximal antileukemic effect. [42] [43] [44] [45] In addition, a treatment duration of 7 days is conventional in human AML treatment and has been shown to be adequate for AML tumor reduction by cytostatic drugs. Lower doses of drugs are, in general, better tolerated and the duration of the treatment can thus be extended without an increased risk of treatment-related toxicity. However, it can also lead to a reduced antileukemic effect. Additional experiments with DT-huGM-CSF show antileukemic effect at the roughly 10-fold reduced dose of 6.25 g/kg/day. The efficacy was found to be dose-dependent. Prolonged treatment at the low dose levels might increase the antileukemic effect. The toxic deaths at dose levels above the MTD in the SCID mice occurred as a consequence of liver failure (data not shown). This is in agreement with localization studies of DT-huGM-CSF performed in SCID mice 46 which suggest that the liver is a major site of uptake and clearance.
Treatment of mice with overt leukemia at day 40 was effective, as demonstrated by reduced leukemia loads after completion of treatment. However, significant AML regrowth was observed by day 80, suggesting that the number of primitive leukemic cells with proliferative capacities had increased in the interval between transplantation and day 40 and could not be eliminated by one course of DT-huGM-CSF treatment. This is in agreement with the observation that the numbers of primitive and committed progenitors of normal bone marrow increase after transplantation in immunodeficient mice. [47] [48] [49] Prolonged treatment or repeated treatment cycles may increase the efficacy of DT-huGM-CSF.
The data on antileukemic activity presented here in combination with the lack of toxicity to normal primitive hemopoietic progenitor cells 22 warrant further development towards clinical application of these novel agents. However, before entering a clinical phase I study the toxic side-effects of DThuGM-CSF should be evaluated in other animal models. The rhesus monkey, employed earlier for a preclinical evaluation of huGM-CSF, 50, 51 could be used as a suitable preclinical animal model to test for specific toxic side-effects. In addition, DT-huGM-CSF-binding studies of human tissues could predict in vivo toxicity.
There is no cross-reactivity between huGM-CSF and the murine GM-CSF receptor and hence also not with DT-huGM-CSF. For a determination of the therapeutic window for DT-GM-CSF, its toxicity and its efficacy should be addressed within a syngeneic system, ie to use the murine variant DTmGM-CSF and to determine the MTD in mice and to use a murine leukemia cell line with GM-CSF-R expression to test the corresponding anti-leukemic efficacy.
The relationship between response and pre-existing antibody titers for the recombinant toxins, such as anti-DT or anti-GM-CSF was not investigated. In phase I/II studies with DT 486 -IL-2, contradictory results were reported about immunogenicity. While some investigators reported that the presence of circulating antibodies did not have an effect on the antitumor response, 52, 53 others reported a negative effect on the efficacy. 54 The question of whether the immunogenicity of DT-huGM-CSF will limit its antileukemic effect should be addressed in clinical studies.
